RT Book, Section
A1 Kirchain, William
A1 Allen, Rondall E.
A2 DiPiro, Joseph T.
A2 Yee, Gary C.
A2 Michael Posey, L.
A2 Haines, Stuart T.
A2 Nolin, Thomas D.
A2 Ellingrod, Vicki L.
SR Print(0)
ID 1189916909
T1 Drug-Induced Liver Injury
T2 DiPiro: Pharmacotherapy A Pathophysiologic Approach, 12e
YR 2021
FD 2021
PB McGraw Hill
PP New York, NY
SN 9781260116564
LK accesspharmacy.mhmedical.com/content.aspx?aid=1189916909
RD 2022/07/01
AB KEY  CONCEPTS  Through  its  normally  functioning  enzymes  and  processes  the  liver  often  causes  a  drug  to  become  toxic  through  a  process  known  as  bioactivation.  Drug-induced  liver  injury  (DILI)  can  have  many  different  clinical  presentations:  idiosyncratic  reactions,  allergic  hepatitis,  toxic  hepatitis,  chronic  active  toxic  hepatitis,  toxic  cirrhosis,  and  liver  vascular  disorders.  The  mechanisms  of  DILI  are  diverse,  representing  many  phases  of  biotransformation,  and  are  susceptible  to  genetic  polymorphism.  The  assessment  of  a  possible  liver  injury  caused  by  drugs  should  include  what  is  known  in  the  literature,  the  timing  involved,  the  clinical  course,  and,  always,  an  exploration  for  preexisting  conditions  that  may  have  encouraged  the  lesion’s  development.  Liver  enzyme  assays  in  serum  can  help  to  determine  if  a  particular  type  of  liver  damage  is  present.  Monitoring  for  DILI  must  be  tailored  to  the  drug  and  the  patient’s  potential  risk  factors.